Loading
A phase 2 trial of Regorafenib in hepatocellular carcinoma, run by Zhejiang Hisun Pharmaceutical Co. Ltd., now recruiting.
Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma is a phase 2 interventional study registered as NCT07310173 by Zhejiang Hisun Pharmaceutical Co. Ltd., with 75 participants planned, started 2026-01-01 and due to reach its primary completion in 2027-10-01. Interventions recorded: AST-3424, Regorafenib Tablets. Conditions listed: HCC - Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Regorafenib, Advanced hepatocellular carcinoma (BCLC C), Anti-angiogenic therapy, Hepatocellular carcinoma.
Shares Advanced hepatocellular carcinoma (BCLC C), Anti-angiogenic therapy, Hepatocellular carcinoma, Small-molecule kinase inhibitors.
Shares Advanced hepatocellular carcinoma (BCLC C), Anti-angiogenic therapy, Hepatocellular carcinoma, Small-molecule kinase inhibitors.
Shares Regorafenib, Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares Advanced hepatocellular carcinoma (BCLC C), Anti-angiogenic therapy, Hepatocellular carcinoma, Small-molecule kinase inhibitors.
Shares Regorafenib, Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares Regorafenib, Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares Regorafenib, Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/